OVERVIEW OF EU APPROVED BIOSIMILARS – update as of 18 January 2022 (based on CHMP 13-16 December 2021 meeting)
Currently, there are 71 biosimilar products that have been authorized for marketing in all EU Member States, as well as in the Economic Area countries Iceland, Liechtenstein and Norway. Based on the latest publicly available information, 14 biosimilar candidates are currently under evaluation at the European Medicines Agency.
More information and product overviews are accessible via this link and the links below:
–Overview of EU licensed biosimilars, sorted by authorization date
–Overview of EU license biosimilars, sorted by INN
Volg ons via: